Cryptotanshinone | CAS#35825-57-1 | STAT3 inhibitor

MedKoo Cat#: 600125 | Name: Cryptotanshinone

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cryptotanshinone is isolated from the root of the Asian medicinal plant, Salvia miotiorrhiza bunge. The compound is a potent STAT3 inhibitor. Cryptotanshinone rapidly inhibited STAT3 Tyr705 phosphorylation through a JAK2-independent mechanism. Cryptotanshinone selectively inhibits STAT3-activated cell lines through binding to monomer STAT3, subsequently blocking the dimerization and inhibiting STAT3 transcriptional regulatory activity. It has been reported in the past that the compound counteracts inflammation through the inhibition of cyclooxygenase II activity and endothelin-1 expression.

Chemical Structure

Cryptotanshinone

CAS#35825-57-1

Theoretical Analysis

MedKoo Cat#: 600125

Name: Cryptotanshinone

CAS#: 35825-57-1

Chemical Formula: C19H20O3

Exact Mass: 296.1412

Molecular Weight: 296.36

Elemental Analysis: C, 77.00; H, 6.80; O, 16.20

Price and Availability

Size	Price	Availability
100mg	USD 250.00	2 Weeks
250mg	USD 450.00	2 Weeks
1g	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Cryptotanshinon; Tanshinone C; Cryototanshinone

IUPAC/Chemical Name

(1R)-1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione

InChi Key

GVKKJJOMQCNPGB-JTQLQIEISA-N

InChi Code

InChI=1S/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,10H,4-5,8-9H2,1-3H3/t10-/m0/s1

SMILES Code

O=C1C(C2=C(OC[C@@H]2C)C3=CC=C4C(C)(C)CCCC4=C13)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Cryptotanshinone inhibits STAT3 with an IC50 of 4.6 μM.

In vitro activity:

The results showed that CT (cryptotanshinone) significantly inhibited the clonogenicity of SK-Hep1 cells in a concentration-dependent manner (Fig. 2A right panel). The colony size of cells treated with CT (3, 6, 12, 25 mM) was markedly reduced compared to that of control cells (DMSO) and cells treated with 0.1 mM rapamycin (Fig. 2A). Reference: J Cancer Prev. 2021 Jun 30; 26(2): 145–152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249204/

In vivo activity:

CTS (cryptotanshinone) significantly reduced cerebral infarct volume, neurologic deficit scores, pro-inflammatory cytokine production (IL-6, TNF-α, and IL-1β), apoptotic protein expression (cleaved caspase-3) of mice after tMCAO challenge. Reference: World J Gastrointest Oncol. 2021 Jul 15;13(7):693-705. https://pubmed.ncbi.nlm.nih.gov/34219678/

	Solvent	mg/mL	mM
Solubility
	DMSO	4.4	14.91
	DMF	1.0	3.37
	Ethanol	10.0	33.74

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 296.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Jeoung NH, Jeong JY, Kang BS. Cryptotanshinone Prevents the Binding of S6K1 to mTOR/Raptor Leading to the Suppression of mTORC1-S6K1 Signaling Activity and Neoplastic Cell Transformation. J Cancer Prev. 2021 Jun 30;26(2):145-152. doi: 10.15430/JCP.2021.26.2.145. PMID: 34258253; PMCID: PMC8249204. 2. Fu X, Zhao W, Li K, Zhou J, Chen X. Cryptotanshinone Inhibits the Growth of HCT116 Colorectal Cancer Cells Through Endoplasmic Reticulum Stress-Mediated Autophagy. Front Pharmacol. 2021 Jun 17;12:653232. doi: 10.3389/fphar.2021.653232. PMID: 34220498; PMCID: PMC8248532. 3. Chen ZM, Hu J, Xu YM, He W, Meng L, Huang T, Ying SC, Jiang Z, Xu AM. Cryptotanshinone inhibits cytotoxin-associated gene A-associated development of gastric cancer and mucosal erosions. World J Gastrointest Oncol. 2021 Jul 15;13(7):693-705. doi: 10.4251/wjgo.v13.i7.693. PMID: 34322198; PMCID: PMC8299932. 4. Zhu F, Chen H, Xu M, Zhang X, Yu J, Pan Y, Zhu W. Cryptotanshinone possesses therapeutic effects on ischaemic stroke through regulating STAT5 in a rat model. Pharm Biol. 2021 Dec;59(1):465-471. doi: 10.1080/13880209.2021.1914672. PMID: 33915069.

In vitro protocol:

In vivo protocol:

1. Chen ZM, Hu J, Xu YM, He W, Meng L, Huang T, Ying SC, Jiang Z, Xu AM. Cryptotanshinone inhibits cytotoxin-associated gene A-associated development of gastric cancer and mucosal erosions. World J Gastrointest Oncol. 2021 Jul 15;13(7):693-705. doi: 10.4251/wjgo.v13.i7.693. PMID: 34322198; PMCID: PMC8299932. 2. Zhu F, Chen H, Xu M, Zhang X, Yu J, Pan Y, Zhu W. Cryptotanshinone possesses therapeutic effects on ischaemic stroke through regulating STAT5 in a rat model. Pharm Biol. 2021 Dec;59(1):465-471. doi: 10.1080/13880209.2021.1914672. PMID: 33915069.

1: Zhang Y, Lu W, Zhang X, Lu J, Xu S, Chen S, Zhong Z, Zhou T, Wang Q, Chen J, Liu P. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res. 2019 Sep;147:104307. doi: 10.1016/j.phrs.2019.104307. Epub 2019 Jun 7. PMID: 31181334. 2: Liu H, Zhan X, Xu G, Wang Z, Li R, Wang Y, Qin Q, Shi W, Hou X, Yang R, Wang J, Xiao X, Bai Z. Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases. Pharmacol Res. 2021 Feb;164:105384. doi: 10.1016/j.phrs.2020.105384. Epub 2020 Dec 19. PMID: 33352229. 3: Liu H, Xie J, Fan L, Xia Y, Peng X, Zhou J, Ni X. Cryptotanshinone Protects against PCOS-Induced Damage of Ovarian Tissue via Regulating Oxidative Stress, Mitochondrial Membrane Potential, Inflammation, and Apoptosis via Regulating Ferroptosis. Oxid Med Cell Longev. 2022 Apr 4;2022:8011850. doi: 10.1155/2022/8011850. PMID: 35419170; PMCID: PMC9001078. 4: Nagappan A, Kim JH, Jung DY, Jung MH. Cryptotanshinone from the Salvia miltiorrhiza Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK/SIRT1 and Nrf2 Signaling Pathways. Int J Mol Sci. 2019 Dec 30;21(1):265. doi: 10.3390/ijms21010265. PMID: 31906014; PMCID: PMC6981483. 5: Li H, Gao C, Liu C, Liu L, Zhuang J, Yang J, Zhou C, Feng F, Sun C, Wu J. A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen. Biomed Pharmacother. 2021 May;137:111332. doi: 10.1016/j.biopha.2021.111332. Epub 2021 Feb 4. PMID: 33548911. 6: Wu YH, Wu YR, Li B, Yan ZY. Cryptotanshinone: A review of its pharmacology activities and molecular mechanisms. Fitoterapia. 2020 Sep;145:104633. doi: 10.1016/j.fitote.2020.104633. Epub 2020 May 20. PMID: 32445662. 7: Wang L, Wang R, Wei GY, Zhang RP, Zhu Y, Wang Z, Wang SM, Du GH. Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism. Pharmacol Res. 2021 Jan;163:105232. doi: 10.1016/j.phrs.2020.105232. Epub 2020 Oct 4. PMID: 33027716. 8: Dalil D, Iranzadeh S, Kohansal S. Anticancer potential of cryptotanshinone on breast cancer treatment; A narrative review. Front Pharmacol. 2022 Sep 16;13:979634. doi: 10.3389/fphar.2022.979634. PMID: 36188552; PMCID: PMC9523165. 9: Wang K, Zhai Q, Wang S, Li Q, Liu J, Meng F, Wang W, Zhang J, Wang D, Zhao D, Liu C, Dai J, Li C, Cui M, Chen J. Cryptotanshinone ameliorates CUS-induced depressive-like behaviors in mice. Transl Neurosci. 2021 Nov 30;12(1):469-481. doi: 10.1515/tnsci-2020-0198. PMID: 34900345; PMCID: PMC8633587. 10: Jiang XT, Qiu Y, Li CH. Cryptotanshinone inhibits oral squamous cell carcinoma through the autophagic pathway. Neoplasma. 2023 Feb;70(1):114-122. doi: 10.4149/neo_2023_220924N957. Epub 2023 Jan 27. PMID: 36704921. 11: Guo X, Ma R, Wang M, Wui-Man Lau B, Chen X, Li Y. Novel perspectives on the therapeutic role of cryptotanshinone in the management of stem cell behaviors for high-incidence diseases. Front Pharmacol. 2022 Aug 15;13:971444. doi: 10.3389/fphar.2022.971444. PMID: 36046823; PMCID: PMC9420941. 12: Wang H, Pang W, Xu X, You B, Zhang C, Li D. Cryptotanshinone Attenuates Ischemia/Reperfusion-induced Apoptosis in Myocardium by Upregulating MAPK3. J Cardiovasc Pharmacol. 2021 Mar 1;77(3):370-377. doi: 10.1097/FJC.0000000000000971. PMID: 33662979. 13: Liu Y, Wang H, Gao J, Wen Z, Peng L. Cryptotanshinone ameliorates the pathogenicity of Streptococcus suis by targeting suilysin and inflammation. J Appl Microbiol. 2021 Mar;130(3):736-744. doi: 10.1111/jam.14810. Epub 2020 Aug 14. PMID: 32750224. 14: Liu JL, Tong L, Luo Y, Gao YJ. [Cryptotanshinone May Induce Ferroptosis of Human Liver Cancer HepG2 Cells]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021 Jun 30;43(3):366-370. Chinese. doi: 10.3881/j.issn.1000-503X.13115. PMID: 34238412. 15: Ashrafizadeh M, Zarrabi A, Orouei S, Saberifar S, Salami S, Hushmandi K, Najafi M. Recent advances and future directions in anti-tumor activity of cryptotanshinone: A mechanistic review. Phytother Res. 2021 Jan;35(1):155-179. doi: 10.1002/ptr.6815. Epub 2020 Aug 10. PMID: 33507609. 16: Chen W, Lu Y, Chen G, Huang S. Molecular evidence of cryptotanshinone for treatment and prevention of human cancer. Anticancer Agents Med Chem. 2013 Sep;13(7):979-87. doi: 10.2174/18715206113139990115. PMID: 23272908; PMCID: PMC3625674. 17: Wang X, Sun Q, Jiang Q, Jiang Y, Zhang Y, Cao J, Lu L, Li C, Wei P, Wang Q, Wang Y. Cryptotanshinone Ameliorates Doxorubicin-Induced Cardiotoxicity by Targeting Akt-GSK-3β-mPTP Pathway In Vitro. Molecules. 2021 Mar 8;26(5):1460. doi: 10.3390/molecules26051460. PMID: 33800264; PMCID: PMC7962658. 18: Chen L, Yang Q, Zhang H, Wan L, Xin B, Cao Y, Zhang J, Guo C. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway. J Ethnopharmacol. 2020 Oct 5;260:113066. doi: 10.1016/j.jep.2020.113066. Epub 2020 Jun 4. PMID: 32505837. 19: Sun JM, Agarwal S, Desai TD, Ju DT, Chang YM, Liao SC, Ho TJ, Yeh YL, Kuo WW, Lin YJ, Huang CY. Cryptotanshinone protects against oxidative stress in the paraquat-induced Parkinson's disease model. Environ Toxicol. 2023 Jan;38(1):39-48. doi: 10.1002/tox.23660. Epub 2022 Sep 20. PMID: 36124540. 20: Lyu D, Jia J. Cryptotanshinone Attenuates Amyloid-β42-induced Tau Phosphorylation by Regulating PI3K/Akt/GSK3β Pathway in HT22 Cells. Mol Neurobiol. 2022 Jul;59(7):4488-4500. doi: 10.1007/s12035-022-02850-2. Epub 2022 May 16. PMID: 35575872.